Our Team

Sid Parulkar, M. Pharm CEO and Founder

With a Master's Degree in Pharmacy and over 20 years of industry experience, Sid brings an impressive breadth of experience and leadership within the biopharmaceutical industry as well as a substantial background in clinical development operations strategy and execution.

Before starting PAR Clinical, Sid held several leadership positions at Aprinoia Therapeutics, Codiak Biosciences, Imara Inc., Blueprint Medicines and others.

"PAR Clinical is a dream project for me with a vision to help clinical-stage start-up biopharma companies meet their organizational milestones by leveraging our trademark SPEO Model. Understanding the current industry needs is critical and our SPEO Model is positioned to address those needs which will not only help early-stage companies resource and cost optimize but extend their financial runway with expediting their drug development timelines "

Strategic Advisory Board

David Mauro M.D., Ph.D

Educated as a pharmacologist, Dr. Mauro received a B.S. in Biochemistry from Cornell University and an M.D./Ph.D. from Temple University. Dr. Mauro has over 20 years of experience in oncology drug development guiding more than 25 Investigational New Drug candidates through development.

Dr. Mauro joined the PAR Clinical Strategic Advisory Board in March 2024 while also serving as a Chief Medical Officer at Recursion, a digital biology company.

Dr. Mauro’s previous roles include serving as the Chief Medical Officer for Codiak Bio Sciences, Checkmate Pharmaceutical, Prelude Therapeutics, and Advaxis. He has also held leadership roles within the clinical and medical affairs teams at Merck, Bristol Myers Squibb, and Becton Dickinson.

Josie Gayton, Ph.D

Dr. Gayton brings over 20 years experience in the biotechnology and pharmaceutical industry and has joined PAR Clinical as a “Strategic Advisory Board” member in May 2024. After graduating from the University of Sussex with a first-class honors degree in Biology with European Studies, she went on to conduct her Ph.D at the Institute of Cancer Research, London.

She has worked in a variety of R&D functions including regulatory affairs, clinical operations and program leadership. Prior to working at Precirix, Josie served as the Senior VP, Program Strategy, Operations and Chief at Staff at Aeglea and has also held several R&D leadership roles at Ipsen and Servier. Josie has extensive experience taking molecules from research into development and then through pivotal clinical trials to successful registration in the US, Europe and Asia.

Faizzan Ahmad Ph.D

Dr. FaizzanAhmad brings over 15 years of pioneering experience in regenerative medicine, longevity, and biotech finance, joining Cure8bio Ventures as a founding visionary and leader in “live” medicines development.

Dr. Ahmad’s journey began with a first-class education at the University of Oxford, where his groundbreaking research in stem cell biology and cardiovascular pharmacology earned prestigious accolades and funding.

Dr. Ahmad's scientific achievements have consistently broken new ground, from establishing a cutting-edge stem cell core facility in Doha to advancing neural regeneration at Johns Hopkins University. Transitioning to biotech finance, he has led numerous investments in innovative biotech companies and served on the boards of directors for pioneering ventures, playing a strategic role in shaping their growth and success.

A recognized thought leader in regenerative medicine, Dr. Ahmad is equally passionate about fostering global innovation ecosystems. He has collaborated with stakeholders across Europe, the Middle East, Central Asia, and the US, championing the development of transformative therapies.

Drew Campbell Ph.D.

A Ph.D. in Pharmaceutical Sciences from the University of Colorado and over 30 years of experience helping people and companies define and achieve success. Dr. Campbell was a faculty member at the Indiana University School of Medicine before transitioning into industry.

Before joining PAR Clinical as a Strategic Advisor, Dr. Campbell held several leadership positions in clinical development and medical affairs at multiple small to large companies.

Manoj Jadhav, Ph.D.

A Ph.D. in Pharmaceutics from Bombay College of Pharmacy and a Post-doctoral Fellowship from the College of Pharmacy and Medicine Univ. of Florida, Dr. Jadhav brings over 18 years of experience in academic and industry research. His experience in pharmaceutical development and regulatory affairs across the US and India working with small molecules and peptide therapeutics in various therapeutic areas is commendable.

While supporting PAR Clinical as a Strategic Advisor, Dr. Jadhav is also serving as the CEO of Isha Therapeutics, exclusively focused on supporting clinical and translational development programs spanning from early to late-stage developments.